Regulatory and Quality Support for Life Sciences Legal Teams

When significant remediation is on the table, experience matters as much as resources.

NSF has supported legal teams and medical device and IVD manufacturers around the world, from emerging companies to some of the industry's leading global organisations, through FDA responses, Warning Letters, significant inspection findings and complex remediation efforts.

NSF's medical device and IVD consultants have led remediation efforts ranging from focused quality system improvements to global programmes, bringing the experience needed to quickly assess the situation and determine the path forward.

Bring experienced remediation resources to the table. Schedule a confidential conversation with an NSF expert.

Our team includes former regulators and industry experts who work alongside legal and executive teams to assess findings, support response development and prepare for the remediation ahead.

NSF partners with legal teams, venture capital firms and M&A teams to provide deep technical expertise in global regulatory compliance and quality systems. We assess regulatory risks, identify compliance gaps, remediate findings from regulators and notified bodies and deliver due diligence that safeguards transactions. Our work spans medical devices, pharmaceuticals, biologics, combination products and clinical trials, helping protect both deal value and long-term regulatory standing.

Premarket strategy and submissions:

We guide clients through regulatory pathways in the EU, UK and US, reducing approval timelines and avoiding regulatory setbacks. Our team supports CE marking, UKCA, FDA 510(k), IDE, NDA, BLA and IND submissions. We ensure that design controls, clinical evidence and CMC packages meet expectations from the EMA, MHRA, FDA and notified bodies from the outset.

Regulatory and quality system remediation:

We address inspection findings and enforcement actions from EMA, MHRA, FDA and notified bodies. Our remediation work strengthens GMP, GCP and GLP compliance by improving audit programmes, CAPA effectiveness, management oversight and supplier quality systems.

Post-market compliance management:

We maintain regulatory compliance across EMEA and US markets through vigilance reporting, pharmacovigilance operations, complaint handling and recall management. Our support ensures continued market access for drugs, biologics, medical devices and combination products after approval.

M&A due diligence and integration:

We assess regulatory and quality risks in acquisitions, divestitures and integration scenarios. Our analysis covers product portfolio compliance, quality system maturity and regulatory exposure across the EU, UK, US and emerging markets. We support both buy-side and sell-side teams with targeted assessments that inform valuation and deal structure, from initial screening through post-close integration or carve-out execution.

Attorney-client privilege protection:

All work is structured under attorney-client privilege, ensuring findings and recommendations support legal strategy while protecting confidential information.

Regulatory authority experience:

Our team comprises former FDA, EMA, MHRA and notified body personnel, as well as industry veterans with direct experience in pharmaceutical manufacturing, medical device development, combination product development and clinical operations. We understand both regulatory expectations and practical compliance challenges.

Rapid deployment capability:

With established expertise across the product lifecycle, we mobilise quickly for time-sensitive engagements, whether supporting emergency product recalls, responding to regulatory enforcement, or conducting expedited due diligence for closing transactions.

Decision-ready deliverables:

We provide actionable outputs, including regulatory risk assessments, compliance gap analyses and implementation roadmaps, along with defined timelines and resource requirements. Each engagement includes structured presentations tailored for legal teams, technical stakeholders, or board-level decision makers.

NSF has extensive, proven experience supporting legal teams, venture capital firms and life sciences manufacturers on complex regulatory and quality matters.